Fate and Celyad’s CAR therapies in oncology offer potential to amplify efficacy with multiple doses

Experts saw potential in CAR NKs like FT596 or CAR T-cell products engineered to express NKG2D like CYAD-101. Credit: CI Photos/Shutterstock.



  • Fate Therapeutics